ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för elesclomol. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2014-04-16

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II).

Hasinoff BB, Yadav AA, Patel D, Wu X.

J Inorg Biochem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jinorgbio.2014.04.004

Bibliografisk träff 2013-11-01

Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.

Corazao-Rozas P, Guerreschi P, Jendoubi M, André F, Jonneaux A, Scalbert C, Garçon G, Malet-Martino M, Balayssac S, Rocchi S, Savina A, Formstecher P, Mortier L, Kluza J, Marchetti P.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.1420

Bibliografisk träff 2013-10-12

Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol.

Vo NH, Xia Z, Hanko J, Yun T, Bloom S, Shen J, Koya K, Sun L, Chen S.

J Inorg Biochem · journal article · DOI 10.1016/j.jinorgbio.2013.10.005

Bibliografisk träff 2013-07-25

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Chen S, Sun L, Koya K, Tatsuta N, Xia Z, Korbut T, Du Z, Wu J, Liang G, Jiang J, Ono M, Zhou D, Sonderfan A.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2013.07.032

Bibliografisk träff 2013-04-28

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II).

Yadav AA, Patel D, Wu X, Hasinoff BB.

J Inorg Biochem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jinorgbio.2013.04.013

Bibliografisk träff 2013-02-11

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A.

J Clin Oncol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2012.44.5585

Bibliografisk träff 2012-08-03

Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, Corroyer-Dulmont A, Bernaudin M, Malet-Martino M, de Lassalle EM, Maboudou P, Formstecher P, Polakowska R, Mortier L, Marchetti P.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-12-0979

Bibliografisk träff 2012-04-17

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.

Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Lu R, Blackman RK, Barsoum J, Koya K, Wada Y.

Free Radic Biol Med · research support, non-u.s. gov't; journal article · DOI 10.1016/j.freeradbiomed.2012.03.017

Bibliografisk träff 2012-03-14

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.

Alli E, Ford JM.

DNA Repair (Amst) · journal article · DOI 10.1016/j.dnarep.2012.02.003

Bibliografisk träff 2012-01-11

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.

Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, Wada Y, Giaever G, Nislow C.

PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0029798

Bibliografisk träff 2010-09-15

LC-MS/MS and density functional theory study of copper(II) and nickel(II) chelating complexes of elesclomol (a novel anticancer agent).

Wu L, Zhou L, Liu DQ, Vogt FG, Kord AS.

J Pharm Biomed Anal · comparative study; journal article · DOI 10.1016/j.jpba.2010.09.007

Bibliografisk träff 2009-10-13

Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.

O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2008.17.1579

Bibliografisk träff 2009-07-16

Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.

Qu Y, Wang J, Sim MS, Liu B, Giuliano A, Barsoum J, Cui X.

Breast Cancer Res Treat · research support, non-u.s. gov't; journal article · DOI 10.1007/s10549-009-0470-6

Bibliografisk träff 2008-08-01

Elesclomol induces cancer cell apoptosis through oxidative stress.

Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-08-0298

Bibliografisk träff 2008-03-01

Molecule of the month. Elesclomol and obatoclax mesylate.

Författaruppgift saknas

Drug News Perspect · journal article